Lotfollah Davoodi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lotfollah Davoodi has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Armaghan Kazeminejad
Department of Dermatology, Antimicrobial Resistance Research Center, Communicable Diseases Institute Mazandaran University of Medical Sciences Sari Iran
5 shared publications - Alireza Razavi
Research Center for Clinical Virology Tehran University of Medical Science Tehran Iran
4 shared publications - Eissa Soleymani
Department of Clinical Laboratory Science Babol Branch, Islamic Azad University Babol Iran
3 shared publications - Azadeh Mizani
Department of Parasitology Pasteur Institute of Iran Tehran Iran
2 shared publications - Farhang Babamahmoodi
Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications - Hamed Jafarpour
Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications
Latest Publications
- Open Access
- 6 October 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (19-20) , e24968
A fatal Candida albicans pericarditis presenting with cardiac tamponade after COVID‐19 infection and cardiothoracic surgery
Background: Candida pericardial infection is a rare clinical entity usually related to recent cardiothoracic surgery and chronic debilitating conditions. During the COVID‐19 pandemic, invasive fungal infections have been on the rise, likely due to a combination of factors such as immunosuppression, underlying conditions like diabetes, and surgical procedures.Case Presentation: Herein, we report a 67‐year‐old diabetic woman with a history of COVID‐19 infection who received a high dose of corticosteroids a few months before admission, and previous myocardial infarction for more than 12 years. The patient had a positive cardiac tamponade with signs of dyspnea, chest pain, and low blood pressure. Echocardiographic data were more in favor of constrictive pericarditis. The patient underwent urgent echocardiography‐guided pericardiocentesis and then broad‐spectrum antibiotic treatment was prescribed. Repeated echocardiography implied a persistent pericardial effusion 10 days later. Subxiphoid aspirates and biopsied tissues showed budding yeast cells and yeast colonies grew on culture media identified as Candida albicans.Conclusion: This report should bring to the attention of physicians toward the possibility of Candida pericardial infection presenting with cardiac tamponade after COVID‐19 infection and cardiothoracic surgery. Echocardiographic assessment, prompt pericardiotomy, molecular‐based identification of causative agent, and early administration of appropriate antifungal treatment should improve the patient's survival.
- 6 October 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (19-20) , e24968
Open AccessA fatal Candida albicans pericarditis presenting with cardiac tamponade after COVID‐19 infection and cardiothoracic surgery
Background: Candida pericardial infection is a rare clinical entity usually related to recent cardiothoracic surgery and chronic debilitating conditions. During the COVID‐19 pandemic, invasive fungal infections have been on the rise, likely due to a combination of factors such as immunosuppression, underlying conditions like diabetes, and surgical procedures.Case Presentation: Herein, we report a 67‐year‐old diabetic woman with a history of COVID‐19 infection who received a high dose of corticosteroids a few months before admission, and previous myocardial infarction for more than 12 years. The patient had a positive cardiac tamponade with signs of dyspnea, chest pain, and low blood pressure. Echocardiographic data were more in favor of constrictive pericarditis. The patient underwent urgent echocardiography‐guided pericardiocentesis and then broad‐spectrum antibiotic treatment was prescribed. Repeated echocardiography implied a persistent pericardial effusion 10 days later. Subxiphoid aspirates and biopsied tissues showed budding yeast cells and yeast colonies grew on culture media identified as Candida albicans.Conclusion: This report should bring to the attention of physicians toward the possibility of Candida pericardial infection presenting with cardiac tamponade after COVID‐19 infection and cardiothoracic surgery. Echocardiographic assessment, prompt pericardiotomy, molecular‐based identification of causative agent, and early administration of appropriate antifungal treatment should improve the patient's survival.
- 11 August 2023
- Published by Springer Nature in Acta Parasitologica
- Vol. 68 (3) , 690-698
Microscopic and Molecular Investigation of Intestinal Microsporidia in HIV + /AIDS and Cancer Patients Undergoing Chemotherapy in Mazandaran Province, North of Iran
Background The aim of this study was to identify Enterocytozoon bieneusi and Encephalitozoon spp. in fecal samples of HIV + /AIDS and cancer patients undergoing chemotherapy, and comparing the results to healthy individuals in Mazandaran province, north of Iran. Methods Stool samples were collected from 50 HIV + /AIDS patients, 50 cancer patients, and 50 healthy samples referred to medical centers in north of Iran. Stool samples were kept in 2.5% potassium dichromate at 4 °C, and stained by modified trichrome for light microscopy examination. The multiplex/nested-PCR targeted the small subunit ribosomal RNA (SSU rRNA) gene. To characterize genotypes, the nested PCR products sequenced by Bioneer Company and was subjected to phylogenetic analyses. Results Ten of 50 samples (20%) of HIV + /AIDS patients, 5 of 50 samples (10%) of cancer patients, and 1 of healthy individuals (2%) were microscopically positive. From 50 HIV + / AIDS patients, E. bieneusi and Encephalitozoon spp. were detected in 10 (20%) and 6 (12%) cases, respectively. Furthermore, among cancer patients, 7 (14%) and 2 (4%) cases were E. bieneusi and Encephalitozoon spp., respectively. Out of 50 samples of healthy individuals, only 3 (6%) cases of E. bieneusi were observed. The genotypes D and M were detected among positive samples of E. bieneusi. Conclusions E. bieneusi and then Encephalitozoon spp. are common intestinal microsporidia in HIV + /AIDS patients and cancer patients undergoing chemotherapy in Mazandaran province. E. bieneusi genotype D seems to be the predominant genotype in Mazandaran province. Due to the considerable prevalence of intestinal microsporidia, physicians are advised to pay more attention to this opportunistic infection in high-risk groups.
- 11 August 2023
- Published by Springer Nature in Acta Parasitologica
- Vol. 68 (3) , 690-698
Microscopic and Molecular Investigation of Intestinal Microsporidia in HIV + /AIDS and Cancer Patients Undergoing Chemotherapy in Mazandaran Province, North of Iran
Background The aim of this study was to identify Enterocytozoon bieneusi and Encephalitozoon spp. in fecal samples of HIV + /AIDS and cancer patients undergoing chemotherapy, and comparing the results to healthy individuals in Mazandaran province, north of Iran. Methods Stool samples were collected from 50 HIV + /AIDS patients, 50 cancer patients, and 50 healthy samples referred to medical centers in north of Iran. Stool samples were kept in 2.5% potassium dichromate at 4 °C, and stained by modified trichrome for light microscopy examination. The multiplex/nested-PCR targeted the small subunit ribosomal RNA (SSU rRNA) gene. To characterize genotypes, the nested PCR products sequenced by Bioneer Company and was subjected to phylogenetic analyses. Results Ten of 50 samples (20%) of HIV + /AIDS patients, 5 of 50 samples (10%) of cancer patients, and 1 of healthy individuals (2%) were microscopically positive. From 50 HIV + / AIDS patients, E. bieneusi and Encephalitozoon spp. were detected in 10 (20%) and 6 (12%) cases, respectively. Furthermore, among cancer patients, 7 (14%) and 2 (4%) cases were E. bieneusi and Encephalitozoon spp., respectively. Out of 50 samples of healthy individuals, only 3 (6%) cases of E. bieneusi were observed. The genotypes D and M were detected among positive samples of E. bieneusi. Conclusions E. bieneusi and then Encephalitozoon spp. are common intestinal microsporidia in HIV + /AIDS patients and cancer patients undergoing chemotherapy in Mazandaran province. E. bieneusi genotype D seems to be the predominant genotype in Mazandaran province. Due to the considerable prevalence of intestinal microsporidia, physicians are advised to pay more attention to this opportunistic infection in high-risk groups.
- Open Access
- 31 July 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 5031-5034
New-onset chronic inflammatory demyelinating polyradiculoneuropathy after COVID-19 infection: a case report
Introduction and importance: SARS-CoV-2 infection, besides respiratory symptoms, as cardinal manifestation, may present with neurological involvement. Immune-mediated polyradiculoneuropathy is one of the important neurological complications manifested by COVID-19 mainly includes Guillain–Barré syndrome (GBS), treatment-related fluctuation of GBS, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Also, there are several reports of COVID-19 vaccine-related GBS and CIDP. According to possible severe manifestations of neuropathies like respiratory failure, considering these complications for early diagnosis and treatment is very important. Case presentation: The authors presented a 67-year-old woman with severe weakness in upper and lower extremities, the patient was diagnosed as case with CIDP initiated after COVID-19 virus infection and/or vaccination that experienced one relapse in 11 months. In both episodes, treatment with intravenous immunoglobulin started and the patient respond. Clinical discussion: To the best of our knowledge, this is one of the first reported cases with a typical chronic course of CIDP associated with COVID-19 virus infection and/or vaccination. Conclusion: Considering this complication and differentiation between GBS and CIDP, and then initiating maintenance therapy can prevent long-term disability.
- 31 July 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 5031-5034
Open AccessNew-onset chronic inflammatory demyelinating polyradiculoneuropathy after COVID-19 infection: a case report
Introduction and importance: SARS-CoV-2 infection, besides respiratory symptoms, as cardinal manifestation, may present with neurological involvement. Immune-mediated polyradiculoneuropathy is one of the important neurological complications manifested by COVID-19 mainly includes Guillain–Barré syndrome (GBS), treatment-related fluctuation of GBS, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Also, there are several reports of COVID-19 vaccine-related GBS and CIDP. According to possible severe manifestations of neuropathies like respiratory failure, considering these complications for early diagnosis and treatment is very important. Case presentation: The authors presented a 67-year-old woman with severe weakness in upper and lower extremities, the patient was diagnosed as case with CIDP initiated after COVID-19 virus infection and/or vaccination that experienced one relapse in 11 months. In both episodes, treatment with intravenous immunoglobulin started and the patient respond. Clinical discussion: To the best of our knowledge, this is one of the first reported cases with a typical chronic course of CIDP associated with COVID-19 virus infection and/or vaccination. Conclusion: Considering this complication and differentiation between GBS and CIDP, and then initiating maintenance therapy can prevent long-term disability.
- Open Access
- 17 April 2023
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 6 (1) , 56-61
Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients
BACKGROUND: Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermo-epidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients. AIM: This study aims to assess the effect of topical formulation based on Arnebia euchroma (AE) on lesions induced by EB. MATERIALS AND METHODS: All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16. RESULTS: Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively). CONCLUSION: Hochobeh ointment may be effective in treating EB skin and mucosal lesions.
- 17 April 2023
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 6 (1) , 56-61
Open AccessTopical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients
BACKGROUND: Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermo-epidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients. AIM: This study aims to assess the effect of topical formulation based on Arnebia euchroma (AE) on lesions induced by EB. MATERIALS AND METHODS: All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16. RESULTS: Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively). CONCLUSION: Hochobeh ointment may be effective in treating EB skin and mucosal lesions.
- Open Access
- 28 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (4)
A Descriptive Study of Human Fascioliasis in Qaemshahr, Mazandaran Province, Iran: Its Prevalence and Risk Factors
Background: Fasciolosis as a zoonotic disease is one of the major health and economic problems with worldwide distribution. In some parts of Iran, the prevalence of human fasciolosis has increased over the past decades. Objectives: This study aimed to determine the seroprevalence of human fasciolosis in Qaemshahr, Mazandaran Province, and determine the epidemiological factors associated with the disease. Methods: In this cross-sectional study, 2,418 serum samples were collected from different parts of Qaemshahr, Mazandaran province, and stored at -20°C until further use. The anti-Fasciola IgG antibodies were evaluated using the ELISA method. The demographic factors of the individuals were collected through questionnaires. Results: Anti-Fasciola hepatica antibodies were detected in 60 (2.48%) individuals using ELISA method. Regarding the Fasciola seropositivity, significant differences were observed between age, gender, farmers, consumption of spring water, raw vegetables, anthelminthic drugs, and patients with a history of jaundice (P < 0.05), while no significant correlation were found between anti-Fasciola IgG positivity and consumption of traditional appetizers such as Dalal or processed olive, abdominal pain, patients with gastrointestinal symptoms, in housewives and administrative employees (P > 0.05). Conclusions: We found that 2% of people in Qaemshahr are seropositive for Fasciola infection. Integrated prevention and control strategies are the most effective solution for a decrease in the prevalence of fasciolosis in Qaemshahr, Mazandaran Province.
- 28 September 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (4)
Open AccessA Descriptive Study of Human Fascioliasis in Qaemshahr, Mazandaran Province, Iran: Its Prevalence and Risk Factors
Background: Fasciolosis as a zoonotic disease is one of the major health and economic problems with worldwide distribution. In some parts of Iran, the prevalence of human fasciolosis has increased over the past decades. Objectives: This study aimed to determine the seroprevalence of human fasciolosis in Qaemshahr, Mazandaran Province, and determine the epidemiological factors associated with the disease. Methods: In this cross-sectional study, 2,418 serum samples were collected from different parts of Qaemshahr, Mazandaran province, and stored at -20°C until further use. The anti-Fasciola IgG antibodies were evaluated using the ELISA method. The demographic factors of the individuals were collected through questionnaires. Results: Anti-Fasciola hepatica antibodies were detected in 60 (2.48%) individuals using ELISA method. Regarding the Fasciola seropositivity, significant differences were observed between age, gender, farmers, consumption of spring water, raw vegetables, anthelminthic drugs, and patients with a history of jaundice (P < 0.05), while no significant correlation were found between anti-Fasciola IgG positivity and consumption of traditional appetizers such as Dalal or processed olive, abdominal pain, patients with gastrointestinal symptoms, in housewives and administrative employees (P > 0.05). Conclusions: We found that 2% of people in Qaemshahr are seropositive for Fasciola infection. Integrated prevention and control strategies are the most effective solution for a decrease in the prevalence of fasciolosis in Qaemshahr, Mazandaran Province.
- Open Access
- 22 May 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (6) , e0978
New‐onset myasthenia gravis after novel coronavirus 2019 infection
In the years since the start of the COVID‐19 pandemic, numerous neurological manifestations have been reported following this novel virus. Myasthenia gravis is one of them. Here, we present the patient that was referred to us with myasthenia gravis symptoms after a COVID‐19 infection.
- 22 May 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (6) , e0978
Open AccessNew‐onset myasthenia gravis after novel coronavirus 2019 infection
In the years since the start of the COVID‐19 pandemic, numerous neurological manifestations have been reported following this novel virus. Myasthenia gravis is one of them. Here, we present the patient that was referred to us with myasthenia gravis symptoms after a COVID‐19 infection.
- 1 December 2021
- Published by Elsevier in Gene Reports
- Vol. 25, 101367
Corrigendum to “Strongyloides stercoralis, a neglected parasite in north of Iran with remarkable exposure” [Gene Rep. 24 (2021), 101271 (September)]
- 1 December 2021
- Published by Elsevier in Gene Reports
- Vol. 25, 101367
Corrigendum to “Strongyloides stercoralis, a neglected parasite in north of Iran with remarkable exposure” [Gene Rep. 24 (2021), 101271 (September)]
- Open Access
- 28 November 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (3) , 758-766
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
Background: The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods: This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O2 saturation <95% and compatible symptoms. The primary outcome was hospital discharge within 10 days of randomization. Secondary outcomes included mortality and time to clinical events. The trial is registered on the Iran Registry of Clinical Trials under IRCT20200624047908N1. Results: Between July and October 2020, 1083 patients were randomized to either the sofosbuvir/daclatasvir arm (n = 541) or the placebo arm (n = 542). No significant difference was observed in the primary outcome of hospital discharge within 10 days, which was achieved by 415/541 (77%) in the sofosbuvir/daclatasvir arm and 411/542 (76%) in the placebo arm [risk ratio (RR) 1.01, 95% CI 0.95–1.08, P = 0.734]. In-hospital mortality was 60/541 (11%) in the sofosbuvir/daclatasvir arm versus 55/542 (10%) in the placebo arm (RR 1.09, 95% CI 0.77–1.54, P = 0.615). No differences were observed in time to hospital discharge or time to in-hospital mortality. Conclusions: We observed no significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients.
- 28 November 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (3) , 758-766
Open AccessEvaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
Background: The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods: This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O2 saturation <95% and compatible symptoms. The primary outcome was hospital discharge within 10 days of randomization. Secondary outcomes included mortality and time to clinical events. The trial is registered on the Iran Registry of Clinical Trials under IRCT20200624047908N1. Results: Between July and October 2020, 1083 patients were randomized to either the sofosbuvir/daclatasvir arm (n = 541) or the placebo arm (n = 542). No significant difference was observed in the primary outcome of hospital discharge within 10 days, which was achieved by 415/541 (77%) in the sofosbuvir/daclatasvir arm and 411/542 (76%) in the placebo arm [risk ratio (RR) 1.01, 95% CI 0.95–1.08, P = 0.734]. In-hospital mortality was 60/541 (11%) in the sofosbuvir/daclatasvir arm versus 55/542 (10%) in the placebo arm (RR 1.09, 95% CI 0.77–1.54, P = 0.615). No differences were observed in time to hospital discharge or time to in-hospital mortality. Conclusions: We observed no significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients.
- Open Access
- 1 October 2021
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 9 (4) , 309-312
Therapeutic Approaches of Infantile Acne: A Narrative Review Study
- 1 October 2021
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 9 (4) , 309-312
Open AccessTherapeutic Approaches of Infantile Acne: A Narrative Review Study
- Open Access
- 14 June 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 649675
Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients
Background: Recent studies from multiple countries have shown a high prevalence of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) among severely ill patients. Despite providing valuable insight into the clinical management of CAPA, large-scale prospective studies are limited. Here, we report on one of the largest multicenter epidemiological studies to explore the clinical features and prevalence of COVID-19-associated pulmonary mold infections (CAPMIs) among mechanically ventilated patients.Methods: Bronchoalveolar lavage (BAL) and serum samples were collected for culture, galactomannan (GM), and β-D-glucan (BDG) testing. Patients were classified as probable CAPMI based on the presence of host factors, radiological findings, and mycological criteria.Results: During the study period, 302 COVID-19 patients were admitted to intensive care units (ICUs), among whom 105 were mechanically ventilated for ≥4 days. Probable CAPMI was observed among 38% of patients (40/105), among whom BAL culture of 29 patients turned positive for molds, while galactomannan testing on BAL (GM index ≥1) and serum (GM index >0.5) samples were positive for 60% (24/40) and 37.5% (15/39) of patients, respectively. Aspergillus (22/29; 75.8%) and Fusarium (6/29; 20.6%) constituted 96.5% of the molds isolated. Diaporthe foeniculina was isolated from a COVID-19 patient. None of the patients who presented with CAPMI were treated with antifungal drugs.Conclusion: Despite being prevalent, the absence of appropriate antifungal treatment highlights that CAPMI is a neglected complication among mechanically ventilated COVID-19 patients admitted to ICUs. CAPMI can be caused by species other than Aspergillus.
- 14 June 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 649675
Open AccessPervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients
Background: Recent studies from multiple countries have shown a high prevalence of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) among severely ill patients. Despite providing valuable insight into the clinical management of CAPA, large-scale prospective studies are limited. Here, we report on one of the largest multicenter epidemiological studies to explore the clinical features and prevalence of COVID-19-associated pulmonary mold infections (CAPMIs) among mechanically ventilated patients.Methods: Bronchoalveolar lavage (BAL) and serum samples were collected for culture, galactomannan (GM), and β-D-glucan (BDG) testing. Patients were classified as probable CAPMI based on the presence of host factors, radiological findings, and mycological criteria.Results: During the study period, 302 COVID-19 patients were admitted to intensive care units (ICUs), among whom 105 were mechanically ventilated for ≥4 days. Probable CAPMI was observed among 38% of patients (40/105), among whom BAL culture of 29 patients turned positive for molds, while galactomannan testing on BAL (GM index ≥1) and serum (GM index >0.5) samples were positive for 60% (24/40) and 37.5% (15/39) of patients, respectively. Aspergillus (22/29; 75.8%) and Fusarium (6/29; 20.6%) constituted 96.5% of the molds isolated. Diaporthe foeniculina was isolated from a COVID-19 patient. None of the patients who presented with CAPMI were treated with antifungal drugs.Conclusion: Despite being prevalent, the absence of appropriate antifungal treatment highlights that CAPMI is a neglected complication among mechanically ventilated COVID-19 patients admitted to ICUs. CAPMI can be caused by species other than Aspergillus.